X
FDA says Clovis’ Rubraca could be prostate cancer breakthrough
https://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
Prostate cancer
US court invalidates key patent on J&J’s Zytiga
J&J to appeal decision.
EU regulators back J&J’s Zytiga in early prostate cancer use
New use could give J&J drug edge over Pfizer’s rival
Pfizer confirms $14bn Medivation merger
Drug giant confirms press reports.
Robots don’t improve prostate surgery outcomes, says study
No differences found in urinary function, post-operative complications or days off work.
1 2
